PDPL

PARENTERAL DRUGS (INDIA)

Small Cap BSE: 524689 NSE: PDPL
₹4.45
-0.2 (-4.3%)
As on 04 December, 2022 | 13:18

Parenteral Drugs (India) Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in PARENTERAL DRUGS (INDIA)

Start SIP

Parenteral Drugs (India) Share Price

Parenteral Drugs (India) Share Returns

  • Over 1 Month 36.92%
  • Over 3 Month 20.27%
  • Over 6 Month 20.27%
  • Over 1 Year 12.66%

Parenteral Drugs (India) Key Statistics

P/E Ratio -0.2
PEG Ratio -0
Market Cap Cr 13
Price to Book Ratio -0
EPS -43.1
Dividend 0
Relative Strength Index 66.11
Money Flow Index 67.19
MACD Signal 0.19
Average True Range 0.15

Parenteral Drugs (India) Investment Rating

  • Master Rating:
  • Parenteral Drugs India has an operating revenue of Rs. 8.50 Cr. on a trailing 12-month basis. An annual revenue de-growth of -30% needs improvement, Pre-tax margin of -1284% needs improvement, NULL It is currently FORMING a base in its weekly chart and is trading around 7% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 42 which is a POOR score indicating inconsistency in earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Parenteral Drugs (India) Financials
IndicatorMar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 21233
Operating Expenses Qtr Cr 8566-1
Operating Profit Qtr Cr -6-3-3-33
Depreciation Qtr Cr 274444
Interest Qtr Cr 037353432
Tax Qtr Cr -5-10-9-9-9
Net Profit Qtr Cr 24-35-34-32-25

Parenteral Drugs (India) Technicals

EMA & SMA

Current Price
4.45
-0.2 (-4.3%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 3.99
  • 50 Day
  • 3.74
  • 100 Day
  • 3.61
  • 200 Day
  • 3.43
  • 20 Day
  • 3.79
  • 50 Day
  • 3.63
  • 100 Day
  • 3.58
  • 200 Day
  • 3.43

Parenteral Drugs (India) Resistance and Support

PIVOT
₹4.69
Resistance
First Resistance 4.77
Second Resistance 4.89
Third Resistance 4.97
RSI 66.11
MFI 67.19
MACD Single Line 0.19
MACD 0.3
Support
First Resistance 4.57
Second Resistance 4.49
Third Resistance 4.37

Parenteral Drugs (India) Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,000 100,000 100
Week 1,000 100,000 100
1 Month
6 Month 3,682 368,183 100

Parenteral Drugs (India) Result Highlights

Parenteral Drugs (India) Synopsis

NSE-Medical-Diversified

Parenteral Drugs is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 12.17 Cr. and Equity Capital is Rs. 29.82 Cr. for the Year ended 31/03/2021. Parenteral Drugs (India) Ltd. is a Public Limited Listed company incorporated on 13/12/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC126481 and registration number is 126481.
Market Cap 13
Sales 8
Shares in Float 0.81
No of funds
Yield
Book Value -0.02
U/D Vol ratio 0.8
LTDebt / Equity
Alpha 0.11
Beta 0.11

Parenteral Drugs (India)

Owner NameMar-22Dec-21
Promoters 73.29%73.28%
Mutual Funds 0.01%0.01%
Financial Institutions/ Banks
Individual Investors 21.74%21.97%
Others 4.96%4.74%

Parenteral Drugs (India) Management

Name Designation
Mr. Manohar Lal Gupta Chairman & Non-Exe.Director
Mr. Vinod Kumar Gupta Managing Director & CFO
Mr. Govind Das Garg Whole Time Director
Mr. Dharam Pal Khanna Ind. Non-Executive Director
Mr. Dilip Kumar Sinha Ind. Non-Executive Director
Mrs. Deepali Garhewal Ind. Non-Executive Director
Mr. Manish Verma Ind. Non-Executive Director
Mr. Anil Mittal Non Executive Director

Parenteral Drugs (India) Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Parenteral Drugs (India) Corporate Action

Date Purpose Remarks
2022-05-30 Audited Results & Others Inter alia, to consider : The shifting of registered office of the Company within local limits of the city.
2022-02-14 Quarterly Results
2022-02-02 Others inter alia, To consider appointment of Independent Director and to consider sale, lease or disposal of the whole or substantially the whole of the undertaking of the Company.
2021-11-12 Quarterly Results
2021-08-10 Quarterly Results

Parenteral Drugs (India) FAQs

What is Share Price of Parenteral Drugs (India) ?

Parenteral Drugs (India) share price is ₹4 As on 04 December, 2022 | 13:04

What is the Market Cap of Parenteral Drugs (India) ?

The Market Cap of Parenteral Drugs (India) is ₹13.3 Cr As on 04 December, 2022 | 13:04

What is the P/E ratio of Parenteral Drugs (India) ?

The P/E ratio of Parenteral Drugs (India) is -0.2 As on 04 December, 2022 | 13:04

What is the PB ratio of Parenteral Drugs (India) ?

The PB ratio of Parenteral Drugs (India) is -0 As on 04 December, 2022 | 13:04

Q2FY23